Inclusion Criteria:

          -  Have a histologically confirmed diagnosis of urothelial carcinoma (UC) / muscle
             invasive bladder cancer (MIBC) (T2-T4aN0M0 or T1-T4aN1M0) with predominant (≥50%)
             urothelial histology

          -  Have clinically non-metastatic bladder cancer (N≤1 M0) determined by imaging (computed
             tomography (CT) or magnetic resonance imaging (MRI) of the chest/abdomen/pelvis

          -  Be deemed eligible for Radical Cystectomy (RC) + Pelvic Lymph Node Dissection (PLND)

          -  Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  Have adequate organ function

        Exclusion Criteria:

          -  Has a known additional malignancy that is progressing or has required active
             anti-cancer treatment ≤3 years of study randomization with certain exceptions

          -  Has received any prior systemic treatment for MIBC or non-invasive muscle bladder
             cancer (NMIBC - prior treatment for NMIBC with intravesical BCG/chemotherapy is
             permitted) or prior therapy with an anti- programmed cell death 1 (PD-1),
             anti-programmed cell death ligand 1/ ligand 2 (PD-L1/L2), or anti-cytotoxic
             T-lymphocyte-associated protein 4 (CTLA-4)

          -  Has ≥N2 disease or metastatic disease (M1) as identified by imaging

          -  Is cisplatin-ineligible, as defined by meeting any one of the cisplatin ineligibility
             criteria as per protocol

          -  Has received prior systemic anticancer therapy including investigational agents within
             3 years of randomization or any radiotherapy to the bladder

          -  Has undergone partial cystectomy of the bladder to remove any NMIBC or MIBC

          -  Has received a live or live attenuated vaccine within 30 days before the first dose of
             study intervention

          -  Has a diagnosis of immunodeficiency or has a known history of human immunodeficiency
             virus (HIV) infection. Hepatitis B infection or known active Hepatitis C infection

          -  Has a known psychiatric or substance abuse disorder

          -  Has had an allogenic tissue/solid organ transplant

          -  Has ongoing sensory or motor neuropathy Grade 2 or higher

          -  Has active keratitis (superficial punctate keratitis) or corneal ulcerations

          -  Has a history of uncontrolled diabetes defined as hemoglobin A1c (HbA1c) ≥8% or HbA1c
             7% to <8% with associated diabetes symptoms